Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Hold” from Brokerages

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have received a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $41.3333.

A number of equities analysts have issued reports on the stock. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their target price for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Truist Financial downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a report on Monday, April 13th. Finally, Guggenheim lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. lifted its holdings in Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares during the period. Wells Fargo & Company MN boosted its position in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock opened at $40.50 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals has a 52-week low of $12.74 and a 52-week high of $40.56. The company’s 50 day moving average price is $39.90 and its 200-day moving average price is $32.33. The stock has a market capitalization of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities research analysts forecast that Centessa Pharmaceuticals will post -1.65 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.